Compare JQC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | REPL |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 692.8M |
| IPO Year | N/A | 2018 |
| Metric | JQC | REPL |
|---|---|---|
| Price | $4.76 | $8.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.13 |
| AVG Volume (30 Days) | 823.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.60 | $2.68 |
| 52 Week High | $5.58 | $13.24 |
| Indicator | JQC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 26.33 | 59.10 |
| Support Level | N/A | $8.24 |
| Resistance Level | $5.16 | $8.82 |
| Average True Range (ATR) | 0.05 | 0.57 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 8.62 | 87.19 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.